Skip to main content
. 2024 Feb 25;47(2):e24245. doi: 10.1002/clc.24245

Figure 1.

Figure 1

(A and B) The details of sequential oral triple combination therapy. (C–J) The differences and changed several clinical parameters of patients treated with 6 months between the two oral tiple combination therapies. (K–N) Changes in several echocardiographic parameters of patients treated for 6 months between the two oral tiple combination therapies. Amb, ambrisentan; ERA, endothelin receptor antagonist; Mac, macitentan; PDE5i, phosphodiesterase 5 inhibitor; Rio, riociguat; Sel, selexipag; Sil, sildenafil; Tad, tadalafil.